Most US women undergoing BRCA genetic testing do not receive genetic counseling despite multiple guidelines.
Although a broad BRCA-1/2 genetic testing program has been suggested for all US women, it is not recommended due to cost and lack of benefit.
Multigene testing for hereditary breast and/or ovarian cancer (HBOC) identifies more mutations that are likely to change clinical management.
The risk of breast and ovarian cancer varies with the type and location of BRCA1/2 mutations.
Use of localized correlated spectroscopy (COSY) shows significant changes in women with BRCA1 and BRCA2 mutations.
Carboplatin Associated with Better Outcomes than Docetaxel in Advanced BRCA1/2-mutation Breast CancerDecember 11, 2014
Carboplatin is associated with better outcomes than docetaxel in individuals with BRCA1/2 mutation-harboring breast cancer.
Reduction in BRCA mutation distress in breast cancer patients, unmet information needs with telephone-based, peer-support program.
Olaparib may be effective for the treatment of numerous advanced cancers caused by BRCA1 and BRCA2 mutations.
Celebrity story helped double rates of genetic testing in following six months at one cancer center.
Mutated versions of a gene called PALB2 can dramatically increase a woman's risk of breast cancer, a new study has found.
Majority of BRCA mutation carriers opted for different surgery than initially planned by their surgeons.
Modifiers of cancer risk have been identified for BRCA1/2 mutation carriers, according to a review published online.
A considerable number of women testing negative for BRCA1/2 may have pathogenic mutations in other genes.
Although dire predictions about the ruling on the biotech industry and health care have not come to pass, questions remain regarding the sequence-interpreting experience of the new crop of BRCA testing labs.
For women with a BRCA mutation, delaying oophorectomy beyond age 35 sharply increases the risk of cancer and mortality.
More mutations observed than expected at BRCAPRO scores of less than 40%.
Research has revealed new genetic variants in patients with ovarian cancer that may eventually help detect the disease earlier.
Oophorectomy reduces the risk of developing ovarian, fallopian tube, or peritoneal cancer by 70% in women with BRCA mutations.
Women with BRCA mutations and early-stage breast cancer who underwent bilateral mastectomy vs. unilateral mastectomy are less likely to die from the disease.
Genetic counseling for BRCA 1/2 gene testing delivered via telephone was not inferior to in-person counseling with respect to knowledge gained and perceived stress.
Preliminary results from the IMPACT study support the use of targeted PSA screening based on BRCA genotype.
Women with a family medical history of BRCA mutations should be offered counseling and genetic testing
Women without the BRCA Mutation but with Family History of BRCA2 Are at Higher Risk for Breast CancerDecember 02, 2013
Women from BRCA2 families but without the BRCA mutation still have higher breast cancer risk.
Current events have brought to light issues surrounding BRCA gene mutation testing.
The Supreme Court ruling last week that human genes cannot be patented will lower the cost of BRCA gene tests and open doors to research.
Women whose family history is not linked to BRCA mutations should not undergo genetic testing, according to a U.S. Preventive Services Task Force recommendation.
Survival advantage during three years after diagnosis; no difference in prognosis at 10 years
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML